Arbutus Biopharma Corp (NASDAQ:ABUS) and its partner Genevant Sciences have reached an agreement with Moderna , Inc. (NASDAQ:MRNA) to postpone a patent infringement trial related to Moderna's COVID-19 vaccine, MRNA-1273. The stipulation, filed today with the U.S. District Court for the District of Delaware, proposes a new trial start date of September 24, 2025, to allow for additional discovery time.
This legal action stems from Arbutus and Genevant's claims that Moderna's vaccine infringes on patents they hold. The requested delay is to facilitate the completion of discovery from Moderna and third parties. The revised schedule is pending the court's approval.
The lawsuit highlights the complex nature of intellectual property rights in the pharmaceutical industry, particularly concerning the high-stakes development and commercialization of COVID-19 vaccines. Arbutus, a company specializing in pharmaceutical preparations, has positioned itself in a significant legal battle with Moderna, a leading vaccine developer.
Investors and industry observers are closely monitoring the situation, as outcomes of such litigation can have material implications for the companies involved. The delay in the trial schedule indicates that both parties are preparing for a comprehensive legal process.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.